Sanara MedTech (SMTI) AI Stock Analysis

• Market Cap: $170.31M
• Dividend Yield: N/A
• Average Volume (3M): 47.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: 30.55%
• EPS Growth: -340.19%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -3.40
• Shares Outstanding: 8,935,657
• 10 Day Avg. Volume: 91,934
• 30 Day Avg. Volume: 47,210
• PEG Ratio: -0.24
• Price to Book (P/B): 7.15
• Price to Sales (P/S): 3.25
• P/FCF Ratio: -1.23K
• Enterprise Value/Market Cap: 1.80
• Enterprise Value/Revenue: 3.01
• Enterprise Value/Gross Profit: 3.26
• Enterprise Value/Ebitda: -11.45
• 1Y Price Target: $41.00
• Price Target Upside: 38.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -2
• Revenue Forecast (FY): $105.75M

• Rating: 41 Neutral
• Price Target: $18.00 ▼(-39.02% Downside)

Sanara MedTech's overall score is primarily impacted by its financial struggles and bearish technical indicators. Despite strong revenue growth highlighted in the earnings call, the company's profitability issues and negative valuation metrics weigh heavily on the stock's attractiveness.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Sanara's products, enhancing its market position and supporting long-term business expansion.

Distributor Network Expansion

Expanding the distributor network increases market reach and accessibility, potentially driving future sales growth and strengthening competitive advantage.

Clinical Evidence and Product Initiatives

Strong clinical evidence and new product initiatives enhance credibility and marketability, supporting long-term growth and innovation.

Negative Factors

Discontinuation of Tissue Health Plus

The discontinuation of THP represents a strategic setback, potentially impacting revenue streams and requiring significant cash outlay.

Increased Operating Expenses

Rising operating expenses can erode profitability, limiting the company's ability to reinvest in growth and innovation over the long term.

Rising Debt Levels

Higher debt levels increase financial risk and may constrain future operational and strategic flexibility, impacting long-term stability.

Sanara MedTech Business Overview & Revenue Model

Company Description

Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.

How the Company Makes Money

Sanara MedTech generates revenue primarily through the sale of its advanced wound care products to hospitals, clinics, and healthcare providers. The company employs a direct sales force as well as distribution agreements to reach its customers. Key revenue streams include product sales, licensing agreements for its proprietary technologies, and potential royalties from partnerships with other medical technology firms. Significant partnerships with healthcare organizations and distribution networks enhance its market reach and contribute to its earnings by expanding its product offerings and ensuring wide availability in various healthcare settings.

Sanara MedTech Financial Statement Overview

Summary

Sanara MedTech is experiencing revenue growth but faces significant challenges in profitability and cash flow management. The high gross profit margin is a positive indicator, but the company needs to address its operating expenses and improve its cash flow generation to enhance financial stability. Increasing debt levels and negative equity returns highlight potential financial risks.

Income Statement

Sanara MedTech shows a consistent increase in revenue, with a TTM revenue growth rate of 4.79%. However, the company struggles with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin remains strong at over 90%, suggesting effective cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.28 in the TTM period, indicating a higher reliance on debt financing. Return on equity is negative, reflecting ongoing losses. The equity ratio has decreased, suggesting a lower proportion of equity financing relative to total assets, which could pose risks if financial conditions worsen.

Cash Flow

Sanara MedTech's cash flow position is concerning, with negative free cash flow and a significant decline in free cash flow growth. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is positive but minimal, suggesting limited cash generation relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	101.90M	86.67M	64.99M	45.84M	24.14M	15.59M
Gross Profit	94.01M	78.53M	57.14M	39.48M	21.83M	13.97M
EBITDA	-26.79M	-1.86M	-289.10K	-11.57M	-7.22M	-4.14M
Net Income	-37.49M	-9.66M	-4.30M	-7.94M	-7.92M	-4.36M
Balance Sheet
Total Assets	71.09M	88.09M	73.87M	61.04M	36.40M	9.83M
Cash, Cash Equivalents and Short-Term Investments	14.94M	15.88M	5.15M	8.96M	18.65M	455.37K
Total Debt	47.39M	32.29M	11.79M	819.22K	425.44K	481.38K
Total Liabilities	64.95M	49.18M	29.28M	19.32M	6.24M	3.99M
Stockholders Equity	6.14M	39.40M	44.83M	41.83M	30.64M	6.15M
Cash Flow
Free Cash Flow	-865.50K	-253.08K	-3.51M	-6.30M	-5.56M	-5.68M
Operating Cash Flow	3.77M	-23.78K	-3.25M	-5.55M	-4.81M	-4.03M
Investing Cash Flow	-12.66M	-6.61M	-10.21M	-3.51M	-5.28M	-2.74M
Financing Cash Flow	7.55M	17.37M	9.64M	-627.35K	28.30M	622.33K

Sanara MedTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Negative. The current price of 29.52 is above the 20-day moving average (MA) of 26.47, below the 50-day MA of 29.64, and below the 200-day MA of 30.40, indicating a bearish trend. The MACD of -2.70 indicates Positive momentum. The RSI at 24.51 is Positive, neither overbought nor oversold. The STOCH value of 12.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMTI.

Sanara MedTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	68 Neutral	$188.72M	35.47	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$172.68M	15.25	9.59%	2.09%	-12.35%	-17.20%
STXS	58 Neutral	$247.71M	―	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	46 Neutral	$157.10M	―	-15.30%	―	-43.95%	-620.21%
SMTI	41 Neutral	$170.31M	―	-27.19%	―	30.55%	-340.19%

Sanara MedTech Corporate Events

Sanara MedTech Reports Strong Q3 2025 Growth

Sanara MedTech Inc. is a medical technology company specializing in the development and commercialization of innovative surgical products aimed at improving clinical outcomes and reducing healthcare costs. The company primarily operates in the North American surgical tissue repair market, offering a range of advanced biologic products.

Sanara MedTech’s Earnings Call: Growth Amid Challenges

Sanara MedTech’s recent earnings call painted a picture of robust growth and strategic challenges. The overall sentiment was positive, with the company showcasing strong revenue growth and improved profitability, primarily driven by its core surgical business and strategic network expansion. However, the discontinuation of Tissue Health Plus and rising operating expenses were notable hurdles discussed during the call.

Sanara MedTech Appoints New CEO Ahead of Growth

On August 29, 2025, Sanara MedTech‘s Board of Directors appointed Seth D. Yon as the new President and Chief Executive Officer, effective September 15, 2025, succeeding Ronald T. Nixon, who will continue as Executive Chairman. This leadership transition is part of a strategic initiative to position Sanara for future growth, with Mr. Yon bringing extensive experience from his previous roles within the company, contributing to its significant revenue growth. Additionally, Ashley Mackey was designated as the principal accounting officer, succeeding Elizabeth B. Taylor, who remains the Chief Financial Officer.

The most recent analyst rating on (SMTI) stock is a Hold with a $33.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.

Sanara MedTech’s Earnings Call: Growth Amid Challenges

Sanara MedTech’s recent earnings call painted a picture of robust growth and strategic challenges. The company reported significant revenue growth and profitability improvements in its Surgical segment, driven by strong product sales and enhanced operational efficiency. However, this positive momentum is somewhat tempered by ongoing losses in the THP segment, which necessitates a strategic reevaluation to balance the overall performance.